These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 10639544)
21. Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas. Mitlak BH; Hutchison JS; Kaufman SD; Nussbaum SR Horm Metab Res; 1991 Jul; 23(7):344-6. PubMed ID: 1663481 [TBL] [Abstract][Full Text] [Related]
22. Etiology and current management of cancer-related hypercalcemia. Warrell RP Oncology (Williston Park); 1992 Oct; 6(10):37-43; discussion 43, 47-50. PubMed ID: 1390013 [TBL] [Abstract][Full Text] [Related]
23. Expression of PTHrP and the PTH/PTHrP receptor in purified alveolar epithelial cells, myoepithelial cells, and stromal fibroblasts derived from the lactating rat mammary gland. Wojcik SF; Capen CC; Rosol TJ Exp Cell Res; 1999 May; 248(2):415-22. PubMed ID: 10222133 [TBL] [Abstract][Full Text] [Related]
24. Parathyroid hormone related protein (PTHrP) and breast cancer. de Vernejoul MC; Bouizar Z; Lasmoles F; Tubiana-Hulin M; Spyratos F; Gueris J; Jullienne A Nouv Rev Fr Hematol (1978); 1991; 33(6):485-7. PubMed ID: 1818303 [TBL] [Abstract][Full Text] [Related]
25. Parathyroid hormone-related protein in an esophageal squamous cell carcinoma with tumor-induced hypercalcemia. Jaïs P; Bouizar Z; Binn M; Vissuzaine C; Hayem G; Mignon M; Lewin MJ Am J Gastroenterol; 1997 Feb; 92(2):343-6. PubMed ID: 9040221 [TBL] [Abstract][Full Text] [Related]
26. Biochemistry and pathology of PTH-related gene products. Martin TJ; Moseley JM J Endocrinol Invest; 1992; 15(9 Suppl 6):171-7. PubMed ID: 1300336 [No Abstract] [Full Text] [Related]
27. Myoepithelial cell differentiation in the developing mammary gland: progressive acquisition of smooth muscle phenotype. Deugnier MA; Moiseyeva EP; Thiery JP; Glukhova M Dev Dyn; 1995 Oct; 204(2):107-17. PubMed ID: 8589435 [TBL] [Abstract][Full Text] [Related]
28. Parathyroid hormone-related protein-associated hypercalcemia in probable intravascular lymphoma of B-cell type. Hanihara T; Takahashi T; Shimada T; Mizuguchi M; Yagishita S Am J Hematol; 1996 Oct; 53(2):144-5. PubMed ID: 8892745 [No Abstract] [Full Text] [Related]
29. Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia. Audran M; Minebois-Villégas A; Lortholary A; Legrand E; Pascaretti C; Giraud P; Subra JF; Boasson M; Jallet P Rev Rhum Engl Ed; 1995 Mar; 62(3):189-96. PubMed ID: 7788336 [TBL] [Abstract][Full Text] [Related]
30. PTH-related peptide (PTHrP) in hypercalcemia. Mundy GR; Edwards JR J Am Soc Nephrol; 2008 Apr; 19(4):672-5. PubMed ID: 18256357 [TBL] [Abstract][Full Text] [Related]
31. Parathyroid hormone-related protein and its role in pregnancy, lactation, and neonatal growth and development. Cooper CW Eur J Endocrinol; 1997 May; 136(5):465-6. PubMed ID: 9186263 [No Abstract] [Full Text] [Related]
32. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. Horwitz MJ; Tedesco MB; Gundberg C; Garcia-Ocana A; Stewart AF J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182 [TBL] [Abstract][Full Text] [Related]
33. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. Horwitz MJ; Tedesco MB; Garcia-Ocaña A; Sereika SM; Prebehala L; Bisello A; Hollis BW; Gundberg CM; Stewart AF J Clin Endocrinol Metab; 2010 Mar; 95(3):1279-87. PubMed ID: 20061412 [TBL] [Abstract][Full Text] [Related]
34. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Esbrit P; Alcaraz MJ Biochem Pharmacol; 2013 May; 85(10):1417-23. PubMed ID: 23500550 [TBL] [Abstract][Full Text] [Related]
35. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645 [TBL] [Abstract][Full Text] [Related]
36. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats. Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059 [TBL] [Abstract][Full Text] [Related]
37. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532 [TBL] [Abstract][Full Text] [Related]
38. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. Yood RA; Mazor KM; Andrade SE; Emani S; Chan W; Kahler KH J Gen Intern Med; 2008 Nov; 23(11):1815-21. PubMed ID: 18787907 [TBL] [Abstract][Full Text] [Related]
39. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894 [TBL] [Abstract][Full Text] [Related]
40. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population. Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]